Top

Published in:

01-08-2010 | Research Article

Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide

Authors: Benjamin J. Vesper, Kim M. Elseth, Gabor Tarjan, G. Kenneth Haines III, James A. Radosevich

Published in: Tumor Biology | Issue 4/2010

Abstract

Nitric oxide (NO), a free radical, has been implicated in the biology of human cancers, including breast cancer, yet it is still unclear how NO affects tumor development and propagation. We herein gradually adapted four human breast adenocarcinoma cell lines (BT-20, Hs578T, T-47D, and MCF-7) to increasing concentrations of the NO donor DETA-NONOate up to 600 μM. The resulting model system consisted of a set of fully adapted high nitric oxide (“HNO”) cell lines that are biologically different from the “parent” cell lines from which they originated. Although each of the four parent and HNO cell lines had identical morphologic appearance, the HNO cells grew faster than their corresponding parent cells and were resistant to both nitrogen- and oxygen-based free radicals. These cell lines serve as a novel tool to study the role of NO in breast cancer progression and potentially can be used to predict the therapeutic response leading to more efficient therapeutic regimens.

U.S. Cancer Statistics Working Group, United states cancer statistics: 1999-2005 incidence and mortality web-based report. (2009) http://www.cdc.gov./uscs, Accessed May 14, 2009.

Gonzalez-Anqulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.CrossRef

Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr J. 2009;56:1–7.CrossRefPubMed

Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, et al. Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer. 2008;8:364.CrossRefPubMed

Radisky ES, Radisky DC. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 2007;8:279–87.CrossRefPubMed

Bentz BG, Haines III GK, Radosevich JA. Increased protein nitrosylation in head and neck squamous cell carcinoma. Head Neck. 2000;22:64–70.CrossRefPubMed

Hibbs JB, Vavrin A, Taintor RR. L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol. 1987;138:550–65.PubMed

Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA. 1995;92:4392–6.CrossRefPubMed

Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, et al. The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med. 2008;45:18–31.CrossRefPubMed

10.

Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA. 2004;101:8894–9.CrossRefPubMed

11.

Zhou J, Schmid T, Brune B. HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation. Curr Mol Med. 2004;4:741–51.CrossRefPubMed

12.

Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, et al. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide. 2008;19:73–6.CrossRefPubMed

13.

Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal. 2006;8:1329–37.CrossRefPubMed

14.

Wink DA, Mitchell JB. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med. 1998;25:434–56.CrossRefPubMed

15.

Bentz BG, Haines III GK, Hanson DG, Radosevich JA. Endothelial constitutive nitric oxide synthase (ecNOS) localization in normal and neoplastic salivary tissue. Head Neck. 1998;20:304–9.CrossRefPubMed

16.

Bentz BG, Haines III GK, Lingen MW, Pelzer HJ, Hanson DG, Radosevich JA. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999;108:781–7.PubMed

17.

Chandra R, Haines III GK, Bentz BG, Shah P, Robinson AM, Radosevich JA. Expression of nitric oxide synthase type 3 in reflux-induced esophageal lesions. Otolaryngol Head Neck Surg. 2001;124:442–7.CrossRefPubMed

18.

Chen HHW, Su W-C, Chou C-Y, Guo H-R, Ho S-Y, Que J, et al. Increased expression of nitric oxide synthase and cyclooxygenase-2 is associated with poor survival in cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:1093–100.CrossRefPubMed

19.

Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1994;55:727–30.

20.

Fujimoto H, Sasaki J, Matsumoto M, Suga M, Ando Y, Iggo R, et al. Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn J Cancer Res. 1998;89:696–702.PubMed

21.

Gavilanes J, Moro MA, Lizasoain I, Lorenzo P, Perez A, Leza JC, et al. Nitric oxide synthase activity in human squamous cell carcinoma of the head and neck. Laryngoscope. 1999;109:148–52.CrossRefPubMed

22.

Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP. Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer. 1998;78:534–41.PubMed

23.

Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer. 1998;82:1897–903.CrossRefPubMed

24.

Marrogi AJ, Travis WD, Welsh JA, Khan MA, Rahim H, Tazelaar H, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res. 2000;6:4739–44.PubMed

25.

Thomsen LL, Farais-Eisner R, Chaudhuri G. Nitric oxide: Role in human cervical cancer. In: Moncada S, Stamler J, Gross S, Higgs EA, editors. The biology of nitric oxide part 5. Proceedings of the 4th international meeting on the biology of nitric oxide. London: Portland Press; 1996. p. 289.

26.

Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase in human breast cancer. Br J Cancer. 1995;72:41–4.PubMed

27.

Nakamura Y, Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Nakao K, et al. Nitric oxide in breast cancer: induction of vascular endothelial growth factor-c and correlation with metastasis and poor prognosis. Clin Cancer Res. 2006;12:1201–7.CrossRefPubMed

28.

Glynn S, Boersma B, Martin D, Howe L, Ridnour L, Wink D, et al. iNOS expression is associated with basal-like breast cancer phenotype and predicts poor survival in ERneg breast cancer. Nitric Oxide. 2007;17:S17.CrossRef

29.

Duenas-Gonzalez A, Isales CM, del Mar Abad-Hernandez M, Gonzalez-Sarmiento R, Sangueza O, Rodriguez-Commes J. Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mod Pathol. 1997;10:645–9.PubMed

30.

Bulut AS, Erden E, Sak SD, Doruk H, Kursun N, Dincol D. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch. 2005;447:24–30.CrossRefPubMed

31.

Loibl S, Buck A, Strank C, von Minckwitz G, Roller M, Sinn HP, et al. The role of early expression of inducible nitric oxide synthase in human breast cancer. Eur J Cancer. 2005;41:265–71.CrossRefPubMed

32.

Radosevich JA, Elseth KM, Vesper BJ, Tarjan G, Haines III GK. Long-term adaptation of lung tumor cell lines with increasing concentrations of nitric oxide donor. The Open Lung Cancer Journal. 2009;2:35–44.CrossRef

33.

Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL, et al. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst. 1977;58:1795–806.PubMed

34.

Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J Natl Cancer Inst. 1958;21:1131–47.PubMed

35.

Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973;51:1409–16.PubMed

36.

Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M, et al. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer. 1979;15:659–70.PubMed

37.

Bentz BG, Hammer ND, Milash B, Klein S, Burnett DM, Radosevich JA, et al. The kinetics and redox state of nitric oxide determine the biological consequences in lung adenocarcinoma. Tumor Biol. 2007;28:301–11.CrossRef

38.

Littlewood-Evans AJ, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997;57:5386–90.PubMed

39.

Smith HS. In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue. J Natl Cancer Inst. 1979;62:225–30.PubMed

40.

Castles CG, Fuqua SA, Klotz DM, Hill SM. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res. 1993;53:5934–9.PubMed

41.

Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res. 1994;54:2615–21.PubMed

42.

Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino Jr MA, Shepard HM. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science. 1985;230:943–5.CrossRefPubMed

43.

Poutanen M, Moncharmont B, Vihko R. 17 beta-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res. 1992;52:290–4.PubMed

44.

Brandes LJ, Hermonat MW. Receptor status and subsequent sensitivity of subclones of MCF-7 human breast cancer cells surviving exposure to diethylstilbestrol. Cancer Res. 1983;43:2831–5.PubMed

Title: Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide
Authors: Benjamin J. Vesper
Kim M. Elseth
Gabor Tarjan
G. Kenneth Haines III
James A. Radosevich
Publication date: 01-08-2010
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-010-0028-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Radiation-induced cell death mechanisms

Is Rab25 a tumor promoter or suppressor—context dependency on RCP status?

Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation

CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma

Galectin-3 expression is associated with bladder cancer progression and clinical outcome

Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer